✦ LIBER ✦

Treatment strategy for the corticocortical neuron pathology of Alzheimer's disease

✍ Scribed by D. M. Bowen; P. T. Francis; A. W. Procter; J. V. Halliwell; D. M. A. Mann; D. Neary

Publisher: John Wiley and Sons
Year: 1992
Tongue: English
Weight: 136 KB
Volume: 32
Category: Article
ISSN: 0364-5134
DOI: 10.1002/ana.410320121

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The pathology of Alzheimer's disease: Nu

The pathology of Alzheimer's disease: Numbers count

✍ Robert D. Terry 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 122 KB 👁 1 views

WAL 2014 FU (talsaclidine): A preferenti

WAL 2014 FU (talsaclidine): A preferentially neuron activating muscarinic agonist for the treatment of Alzheimer's disease

✍ Helmut A. Ensinger; Wolf-Dieter Bechtel; Franz W. Birke; Klaus D. Mendla; Joachi 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 150 KB 👁 2 views

The functional selectivity of WAL 2014 FU with regard to stimulation of the neuronal muscarinic M 1 receptor subtype in vitro and in vivo is shown in different receptor preparations, isolated organ models, whole animal testing, and finally humans. From receptor binding experiments in membrane prepar

Advances in the drug treatment of Alzhei

Advances in the drug treatment of Alzheimer's Disease

✍ B. E. Leonard 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 133 KB 👁 2 views

There are two main approaches to the treatment of Alzheimer's disease. The ®rst approach is to prevent the neurodegenerative changes that ultimately cause irreversible damage to the brain. As the excessive formation of betaamyloid protein appears to play a primary role in the neurodegenerative proce

Xanomeline: A selective muscarinic agoni

Xanomeline: A selective muscarinic agonist for the treatment of Alzheimer's disease

✍ Frank P. Bymaster; Celia A. Whitesitt; Harlan E. Shannon; Neil DeLapp; John S. W 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 147 KB 👁 1 views

Xanomeline is a novel muscarinic receptor agonist relatively devoid of parasympathomimetic side effects. Xanomeline had high affinity for muscarinic receptors and much lower affinity for a variety of other neuronal receptors in radioligand binding assays. Functional studies in cell lines transfected

SELEGILINE IN THE TREATMENT OF BEHAVIOUR

SELEGILINE IN THE TREATMENT OF BEHAVIOURAL DISTURBANCE IN ALZHEIMER'S DISEASE

✍ BRIAN A. LAWLOR; PAUL S. AISEN; CYNTHIA GREEN; ELIZABETH FINE; JAMES SCHMEIDLER 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 97 KB 👁 2 views

Objective. The purpose of this study was to examine the behavioural and cognitive eects of selegiline in a group of moderately behaviourally disturbed AD patients. Design. This was a 14-week randomized double-blind placebo-controlled study of selegiline (10 mg) and placebo. Setting. An outpatient

The Recent Updates of Therapeutic Approa

The Recent Updates of Therapeutic Approaches Against Aβ for the Treatment of Alzheimer's Disease

✍ Shucai Ling; Jing Zhou; John A. Rudd; Zhiying Hu; Marong Fang 📂 Article 📅 2011 🏛 Wiley (John Wiley & Sons) 🌐 English ⚖ 194 KB

## Abstract One of the main neuropathological lesions observed in brain autopsy of Alzheimer's disease (AD) patients is the extracellular senile plaques mainly composed of amyloid‐beta (Aβ) peptide. Recently, treatment strategies have focused on modifying the formation, clearance, and accumulation